Suchergebnisse - "Motoi, Noriko"

PubPharm (57)

1

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses

enthalten in: Cancer communications (London, England) | 2024

von Shiraishi, K. | Takahashi, A. | Momozawa, Y. | +81

2

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer

enthalten in: British journal of cancer | 2023

von Shirasawa, M. | Yoshida, T. | Shiraishi, K. | +20

ErratumIn: Br J Cancer. 2023 Nov 3;:. - PMID 37923915

3

Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

enthalten in: Cancer research communications | 2023

von Aoki, K. | Nishito, Y. | Motoi, N. | +38

4

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Shirasawa, M. | Yoshida, T. | Shiraishi, K. | +19

5

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients

enthalten in: Clinical lung cancer | 2022

von Shimoda, Y. | Shibaki, R. | Yoshida, T. | +12

6

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Shirasawa, M. | Yoshida, T. | Imabayashi, T. | +13

CommentIn: Eur J Cancer. 2022 May;167:149-151. - PMID 35307255

7

Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations

enthalten in: Molecular cancer therapeutics | 2022

von Jo, H. | Yagishita, S. | Hayashi, Y. | +13

8

The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma

enthalten in: Cancer treatment and research communications | 2022

von Iizuka, T. | Nagano, H. | Nomura, K. | +4

9

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2021

von Shirasawa, M. | Yoshida, T. | Shimoda, Y. | +18

10

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Yoh, K. | Matsumoto, S. | Furuya, N. | +14

1
2
3
4
5
6
Nächster »
[6]